Considering that the SARS-CoV-2 commonly known as Covid-19 is being considered by the World Health Organization (WHO) as a public health emergency of international concern (PHEIC) – WHO’s highest level of alarm, health researchers worldwide have started conducting trials to fight the Covid-19 pandemic either by providing prevention tools (i.e. Vaccine development) or therapeutics (i.e. Drugs/Medicines).
Three Aminos, LLC, a Georgia/USA-based organization and Rinda Ubuzima a Rwanda-based Non-Governmental Organization, are partnering to conduct a Phase 2, Proof of Concept, Randomized, Double Blind, Placebo Controlled Study to evaluate efficacy and safety of Prothione™ capsules for mild to moderate COVID-19. Given that the time between emergence of first symptoms and serious complications is extended in Covid-19, they believe early intervention with highly efficient pro-glutathione compounds is a safe approach – hence the use of Prothione™ capsules.
The Prothione™ Capsules is an oral formulation administered twice a day in subjects with mild to moderate Covid-19
The proposed clinical study is expected to enrol up to 200 subjects.
The total study duration is up to 44 days:
– Screening period: 7 days
– Treatment period: 30 days
– Follow-up period: 7 days
